Repare Therapeutics (NASDAQ:RPTX) Trading Up 0.8% – What’s Next?

Repare Therapeutics Inc. (NASDAQ:RPTX)’s stock price rose 0.8% on Thursday . The company traded as high as $2.65 and last traded at $2.65. Approximately 1,219,900 shares were traded during trading, an increase of 29% from the average daily volume of 947,968 shares. The stock had previously closed at $2.63.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on the company. TD Cowen cut Repare Therapeutics to a “hold” rating in a research note on Monday, November 17th. Weiss Ratings restated a “sell (d-)” rating on shares of Repare Therapeutics in a research report on Monday, December 22nd. Wall Street Zen upgraded shares of Repare Therapeutics to a “hold” rating in a research note on Saturday, November 15th. Finally, HC Wainwright cut their price objective on Repare Therapeutics from $5.00 to $3.00 and set a “buy” rating for the company in a report on Monday, October 27th. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $3.00.

Repare Therapeutics Stock Up 0.8%

The stock’s 50-day moving average price is $2.54 and its 200 day moving average price is $2.06. The company has a market cap of $114.24 million, a P/E ratio of -1.57 and a beta of 0.97.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in RPTX. XTX Topco Ltd lifted its stake in shares of Repare Therapeutics by 145.9% in the fourth quarter. XTX Topco Ltd now owns 116,933 shares of the company’s stock valued at $304,000 after buying an additional 69,386 shares during the period. Occudo Quantitative Strategies LP acquired a new stake in Repare Therapeutics during the fourth quarter worth $35,000. Yakira Capital Management Inc. bought a new stake in Repare Therapeutics in the 4th quarter valued at $693,000. Marshall Wace LLP bought a new position in shares of Repare Therapeutics during the 4th quarter worth about $2,901,000. Finally, Walleye Capital LLC bought a new position in shares of Repare Therapeutics during the 4th quarter worth about $277,000. Institutional investors own 85.09% of the company’s stock.

Repare Therapeutics Company Profile

Repare Therapeutics, traded on NASDAQ under the symbol RPTX, is a clinical-stage biopharmaceutical company focused on the discovery and development of precision oncology medicines. The company applies synthetic lethality—a concept whereby cancer-specific genetic vulnerabilities are exploited—to design small-molecule therapies that selectively kill tumor cells while sparing healthy tissue. Repare’s proprietary functional genomics and screening platform integrates CRISPR-based assays and computational biology to systematically uncover novel genetic interactions and therapeutic targets.

At the core of Repare’s approach is its ability to identify and validate DNA damage response (DDR)-related targets.